Accordingly, HCC tissues sensitive to apoptosis induction by sorafenib and TRAIL revealed enhanced NOXA expression compared to HCC tissues resistant to this treatment combination. This evidence concerns the gene TNFSF10 and hepatocellular carcinoma.